Filtered By:
Specialty: Drugs & Pharmacology
Condition: Hemorrhagic Stroke

This page shows you your search results in order of relevance. This is page number 16.

Order by Relevance | Date

Total 692 results found since Jan 2013.

Low-dose intravenous recombinant tissue plasminogen activator in acute ischemic stroke without large vessel occlusion screened by 3T MRI
CONCLUSIONS: Our study indicates the efficacy and safety of low-dose rTPA treatment for AIS without LVO within 4.5 hours. Patient selection for rTPA by 3T MRI decreased complications and mortality.PMID:37522667 | DOI:10.26355/eurrev_202307_33126
Source: European Review for Medical and Pharmacological Sciences - July 31, 2023 Category: Drugs & Pharmacology Authors: Q-S Huynh C-C Tran H-T Nguyen-Thi T-T Nguyen H-L Phan-Thi D-T Luu-Dang M-T Le M-D Nguyen Source Type: research

Angiotensin-(1-7) Counteracts the Effects of Ang II on Vascular Smooth Muscle Cells, Vascular Remodeling and Hemorrhagic Stroke: Role of the NFкB Inflammatory Pathway.
In conclusion, Ang-(1-7) counteracts the effects of Ang II on ICH via modulating NFκB inflammation pathway in HBVSMCs and cerebral microvessels. PMID: 26264508 [PubMed - as supplied by publisher]
Source: Vascular Pharmacology - August 8, 2015 Category: Drugs & Pharmacology Authors: Bihl JC, Zhang C, Zhao Y, Xiao X, Ma X, Chen Y, Chen S, Zhao B, Chen Y Tags: Vascul Pharmacol Source Type: research

Desmoteplase for Acute Ischemic Stroke: A Systematic Review and Meta-analysis of RCTs.
CONCLUSION: Current evidence suggests a favorable reperfusion effect for desmoteplase within 3 to 9 hours after AIS. Further large RCTs, particularly using a moderate dose between 90 µg/kg and 125 µg/kg are needed to translate this successful reperfusion into better clinical outcome and better quality of life for AIS patients. PMID: 27978795 [PubMed - as supplied by publisher]
Source: CNS and Neurological Disorders Drug Targets - December 12, 2016 Category: Drugs & Pharmacology Authors: Elmaraezy A, Abushouk AI, Saad S, Eltoomy M, Mahmoud O, Hassan HM, Aboelmakarem A, Aboel Fotoh A, Althaher F, Huy NT, Hirayama K Tags: CNS Neurol Disord Drug Targets Source Type: research

Alteplase for acute ischemic stroke after heparin reversal with protamine – a case report and review
ConclusionsGiven the lack of adverse events associated with IV alteplase in our patient, we advocate cautious evaluation for potential reversal of acutely administered anticoagulation to facilitate alteplase administration in severely disabled patients who are not eligible for mechanical intervention, and who would have been excluded from definitive AIS treatment.This article is protected by copyright. All rights reserved.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - July 25, 2017 Category: Drugs & Pharmacology Authors: Gabriel V. Fontaine, Shawn M. Smith Tags: Case Report Source Type: research

Alteplase for Acute Ischemic Stroke after Heparin Reversal with Protamine: A Case Report and Review
We describe the first reported case of a patient receiving full‐dose intravenous (IV) alteplase for AIS after heparin reversal with protamine. A 73‐year‐old man presented with AIS. He was treated with IV heparin, tirofiban, loading‐dose prasugrel, and aspirin before percutaneous coronary intervention (PCI) for placement of a right coronary artery stent. One hour following PCI, he abruptly developed left hemiparesis and dysphagia. The National Institutes of Health Stroke Scale was 12, and activated partial thromboplastin time (aPTT) was longer than 150 seconds. Head computed tomography (CT) showed no acute patholog...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - September 4, 2017 Category: Drugs & Pharmacology Authors: Gabriel V. Fontaine, Shawn M. Smith Tags: Case Report Source Type: research

Efficacy of SMTP ‐7, a small‐molecule anti‐inflammatory thrombolytic, in embolic stroke in monkeys
In conclusion, SMTP‐7 is effective in treating severe embolic stroke in monkeys under conditions where t‐PA treatment tends to cause hemorrhagic infarct‐associated premature death.
Source: Pharmacology Research and Perspectives - December 5, 2018 Category: Drugs & Pharmacology Authors: Eriko Suzuki, Naoko Nishimura, Tetsuya Yoshikawa, Yudai Kunikiyo, Keiko Hasegawa, Keiji Hasumi Tags: ORIGINAL ARTICLE Source Type: research

Hemorrhagic conversion after alteplase administration in a patient with vasculitis and acute ischemic stroke.
Conclusion: More data regarding alteplase treatment in patients with GPA are needed to further establish the safety of this therapy. PMID: 30689698 [PubMed - as supplied by publisher]
Source: American Journal of Health-System Pharmacy : AJHP - January 19, 2019 Category: Drugs & Pharmacology Authors: Gilbert BW, Dhakal L, Lacy A, Huffman JB Tags: Am J Health Syst Pharm Source Type: research